Incidence and Determinants of Hematotoxicity in Acute Lymphoblastic Leukemia Children Who Received 6-mercaptopurine Based Maintenance Therapy in Addis Ababa, Ethiopia

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jun 2

PMID 37267380

Authors

Awol Mekonnen Ali

Haileyesus Adam

Daniel Hailu

Marieke J H Coenen

Rawleigh Howe

Teferra Abula

Affiliations

Soon will be listed here.

Abstract

Introduction: The maintenance phase of acute lymphoblastic leukemia treatment is the final and longest stage of treatment, mainly focused on antimetabolite therapy. This phase is essential to eliminate residual leukemic clones and prevent relapse. However, dose-limiting hematotoxicity is a major problem during this phase resulting in dose reduction or treatment discontinuation.

Objective: In this cohort study, the clinical features and risk factors of hematological toxicity during the maintenance phase of treatment were analyzed in pediatric patients from Ethiopia.

Methods: A total of 160 patients from Tikur Anbessa specialized hospital were included in the study of which 142 had sufficient data available for analysis. Patient characteristics as well as information about the care-givers, sides-effects as reported by the care-givers and clinical factors were collected. Bivariable followed by multivariable analysis was performed to investigate which factors were associated with hematological toxicity during the maintenance phase.

Results: During the first six months of maintenance phase treatment grade 4 neutropenia was detected in 52.8% of the patients. The risk of developing grade 4 neutropenia was increased by about two fold in children with the age of 6 years and less compared to those with the age of more than 6 years. Similarly, the rate of developing grade 4 neutropenia among children with less than 4,500 maintenance day 1 white blood cell counts was significantly higher than that of children with normal maintenance day 1 white blood cell counts (AHR 2.477, 95% CI = 1.461-4.200, p = 0.001).

Conclusion: In conclusion, child's age and day 1 maintenance white blood cell/absolute neutrophil counts significantly affected the occurrence of grade 4 hematotoxicity. Close monitoring for white blood cell and absolute neutrophil counts during maintenance phase treatment is recommended for early diagnosis of hematotoxicity.

References

Jabeen K, Ashraf M, Iftikhar S, Belgaumi A . The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC). J Pediatr Hematol Oncol. 2016; 38(8):587-596. DOI: 10.1097/MPH.0000000000000653. View

Rosdiana D, Setiabudy R, Andalusia R, Gatot D, Louisa M, Bardosono S . Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy. Pharmgenomics Pers Med. 2021; 14:199-210. PMC: 7868246. DOI: 10.2147/PGPM.S288988. View

Memirie S, Kifle Habtemariam M, Asefa M, Deressa B, Abayneh G, Tsegaye B . Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data. J Glob Oncol. 2018; 4:1-11. PMC: 6223441. DOI: 10.1200/JGO.17.00175. View

Bahnassy A, Abdellateif M, Zekri A . Cancer in Africa: Is It a Genetic or Environmental Health Problem?. Front Oncol. 2021; 10:604214. PMC: 7781064. DOI: 10.3389/fonc.2020.604214. View

Teachey D, Hunger S, Loh M . Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood. 2020; 137(2):168-177. PMC: 7820874. DOI: 10.1182/blood.2020007702. View

Badr M, Hassan T, Sakr H, Karam N, Abdel Rahman D, Shahbah D . Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. Mol Clin Oncol. 2016; 5(3):300-306. PMC: 4998081. DOI: 10.3892/mco.2016.957. View

Lyman G, Lyman C, Agboola O . Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10(6):427-37. DOI: 10.1634/theoncologist.10-6-427. View

Hunger S, Sung L, Howard S . Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatr Blood Cancer. 2009; 52(5):559-65. DOI: 10.1002/pbc.21889. View

Ahmed J, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M . CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. Front Pharmacol. 2019; 10:481. PMC: 6527746. DOI: 10.3389/fphar.2019.00481. View

10.

Sitaresmi M, Mostert S, Purwanto I, Gundy C, Sutaryo , Veerman A . Chemotherapy-related side effects in childhood acute lymphoblastic leukemia in Indonesia: parental perceptions. J Pediatr Oncol Nurs. 2009; 26(4):198-207. DOI: 10.1177/1043454209340315. View

11.

Relling M, Hancock M, Boyett J, Pui C, Evans W . Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999; 93(9):2817-23. View

12.

Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

13.

Lyman G . Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009; 7(1):99-108. DOI: 10.6004/jnccn.2009.0009. View

14.

Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K . The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res. 2011; 36(5):560-4. DOI: 10.1016/j.leukres.2011.11.015. View

15.

Bhatt V, Saleem A . Review: Drug-induced neutropenia--pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004; 34(2):131-7. View

16.

Rudin S, Marable M, Huang R . The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics. 2017; 15(2):82-93. PMC: 5414888. DOI: 10.1016/j.gpb.2016.11.003. View

17.

Johnston W, Erdmann F, Newton R, Steliarova-Foucher E, Schuz J, Roman E . Childhood cancer: Estimating regional and global incidence. Cancer Epidemiol. 2020; 71(Pt B):101662. DOI: 10.1016/j.canep.2019.101662. View

18.

Wahlund M, Nilsson A, Zimdahl Kahlin A, Broliden K, Hed Myrberg I, Appell M . The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia. J Pediatr. 2019; 216:150-157.e1. DOI: 10.1016/j.jpeds.2019.09.024. View

19.

Hosmer W, Malin J, Wong M . Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2010; 19(3):333-41. PMC: 3046362. DOI: 10.1007/s00520-010-0821-1. View

20.

Crawford J, Dale D, Lyman G . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2):228-37. DOI: 10.1002/cncr.11882. View